Adaptimmune Therapeutics Plc, a cell therapy company, has promoted Joanna Brewer to the newly created position of chief scientific officer. She was previously senior vice president for allogeneic research where she helped develop prospective iPSC-derived allogeneic T cell therapies for cancer. Dr Brewer holds a master’s degree in natural sciences and a PhD in cellular signalling, both from the University of Cambridge, UK.
Adaptimmune announced the appointment on 4 May 2022.
Copyright 2022 Evernow Publishing Ltd